DocGo Inc.
NASDAQ:DCGOMedical - Care Facilities
-$0.02 today
- Market cap
- $70.14M
- Beta
- 1.00
- P/E (TTM)
- -0.3
- EPS (TTM)
- -$1.90
Volume 1.64M
Average 0.87M
DCGO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
DocGo Inc.NASDAQ: DCGO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $3.22M fell 33.2% year over year, behind the +9.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.8% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.
Context
- Stock-based compensation amounted to 5.4% of revenue in FY2025, up 3.2 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -33.2% toward the trailing-twelve-month pace of +9.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 17.44M USD
- Year-over-year change
- +27.9%
- 4-year CAGR
- +88.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.44M | +27.9% |
| FY2024 | 2024-12-31 | 13.63M | -35.0% |
| FY2023 | 2023-12-31 | 20.97M | +160.3% |
| FY2022 | 2022-12-31 | 8.05M | +485.2% |
| FY2021 | 2021-12-31 | 1.38M | — |
Stock-Based Compensation vs competitors
How DCGO compares with its peers on the latest reported figures
- DCGO's LTM Mar 2026 stock-based compensation of $15.84M is the largest of the 9 companies compared; the peer median is $3.91M.
- Its year-over-year change of +9.4% is the 2nd highest of 9, against a peer median of -19.1%.
- Stock-based compensation amounts to 5.2% of revenue for DCGO, versus a peer median of 47.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.84M | +9.4% | +29.4% | 5.2% | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $10.08M | -60.8% | -22.0% | 60.3% | |
| LTM Mar 2026 | $7.93M | -41.7% | +10.8% | 11.0% | |
| LTM Mar 2026 | $5.41M | +63.4% | +174.5% | 68.1% | |
| LTM Mar 2026 | $2.41M | -6.9% | -9.8% | 33.9% | |
| LTM Mar 2026 | $2.15M | -27.0% | +57.6% | — | |
| LTM Mar 2026 | $1.45M | -10.0% | +4.6% | — | |
| LTM Mar 2026 | $1.02M | -11.2% | -15.5% | 974.3% | |
| Peer median (excluding DCGO) | $3.91M | -19.1% | -2.6% | 47.1% | |
Competitors are the stored peer set for DCGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 19.18M | 30.74M | 6.86M | 19.99M | (196.37M) |
| Depreciation & Amortization | 7.07M | 10.57M | 16.43M | 15.88M | 15.66M |
| Deferred Income Tax | (630.38K) | (9.96M) | (1.98M) | 3.47M | 7.75M |
| Stock-Based Compensation | 1.38M | 8.05M | 20.97M | 13.63M | 17.44M |
| Change in Working Capital | (28.8M) | (13.18M) | (113.12M) | 19.52M | 81.66M |
| Accounts Receivables | (58M) | (8.42M) | (160.52M) | 41.27M | 112.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 11.88M | 3.64M | (1.78M) | 8.56M | (17.64M) |
| Other Working Capital | 17.31M | (8.4M) | 49.18M | (30.32M) | (13.19M) |
| Other Non-Cash Items | (142.67K) | 2.64M | 6.62M | (2.16M) | 108.31M |
| Operating Cash Flow | (1.95M) | 28.87M | (64.22M) | 70.34M | 34.45M |
| Capital Expenditures | (6.66M) | (5.5M) | (10.13M) | (5.84M) | (7.43M) |
| Acquisitions (Net) | (1.96M) | (32.95M) | (19.46M) | (310.45K) | (16.4M) |
| Purchases of Investments | (655.88K) | 0 | 0 | (5M) | 0 |
| Sales of Investments | 655.88K | 0 | 0 | 0 | 13.16M |
| Other Investing Activities | (1.82M) | (2.3M) | (2.84M) | (1.73M) | (31.3M) |
| Investing Cash Flow | (8.59M) | (38.45M) | (29.88M) | (10.87M) | (39.08M) |
| Debt Repayment | (2.82M) | (3.94M) | 20.7M | 613.55K | (35.17M) |
| Common Stock Issued | 178.1M | 0 | 1.58M | 0 | 0 |
| Common Stock Repurchased | (479.33K) | (3.73M) | 0 | (13.76M) | (10.83M) |
| Dividends Paid | 0 | 0 | 0 | (1.29T) | 0 |
| Other Financing Activities | (19.6M) | 1.49M | (21.17M) | 1.29T | (4.82M) |
| Financing Cash Flow | 155.21M | (6.18M) | 1.12M | (24.15M) | (50.82M) |
| Effect of Forex Changes | (21.41K) | 761.23K | 1.09M | (190.64K) | 595.8K |
| Net Change in Cash | 144.65M | (15M) | (91.89M) | 35.12M | (54.85M) |
| Free Cash Flow | (8.6M) | 23.37M | (74.35M) | 64.5M | 27.02M |
DocGo Inc.
NASDAQ:DCGO
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.